A Phase 4 interventional study of Omega-3 and Trehalose in Dry Eye, Dry Eye Syndromes and Cataract, sponsored by Uptown Eye Specialists. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Uptown Eye Specialists · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing omega-3 fatty acid in Dry Eye Syndromes — 1 open to participants now, 1 under way, none of them phase 3. omega-3 fatty acid · Dry Eye Syndromes.
Among the 11 studies testing omega-3 fatty acid in Dry Eye Syndromes, this one is the 6th largest by planned enrollment, is one of 2 that started in 2023, is the only one in phase 4, and was the 11th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →1 of the 11 studies testing omega-3 fatty acid in Dry Eye Syndromes is open now, in 1 country.
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 5 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 68 is above the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 68 across the 11 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 10 most frequent:
Uptown Eye Specialists is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Uptown Eye Specialists has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing omega-3 fatty acid in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study assesses the impact of two differing ocular hygiene regimens prior to cataract surgery. The first regimen includes an omega-3 supplement and the second without, and both include an at-home lid wipe and cleansing eye drops. These regimens will be assessed on microbial load, inflammation, tear osmolarity, and dry eye metrics. Patients will be randomized to either the omega-3 group + 3-part hygiene regimen, or the group with only the 3-part hygiene regimen. Data will be collected for inflammation through a test (InflammaDry) that measures an inflammatory marker, dry eye metrics via an imaging tool called Oculus 5M and the Canadian Dry Eye Assessment (CDEA) questionnaire, tear osmolarity through Tear Labs device, and area of growth for conjunctiva microbial load by swabbing the conjunctiva of the eye. Dry eye metrics (CDEA and Oculus 5M) will be collected during the patient's baseline appointment, 2-5 days prior to surgery, and post-operative month 1. Microbial load swabs will be collected at baseline, 2-5 days prior to surgery, and date of the surgery. An ocular assessment will also be completed at baseline, one week post-operation, and one month post-operation. All metrics will be compared to the fellow eye. The usage of omega-3 will be compared to the regimen without omega-3.
Prospective interventional study assessing the impact of two ocular hygiene regimens, with and without Omega-3, on microbial load, inflammation, tear osmolarity, and dry eye metrics and disease for patients soon to undergo cataract surgery. Study recruitment will occur at Uptown Eye between Sept-Nov 2023, with a target of 68 patients enrolled in the study. Patients will be consecutively randomized to group 1 (without omega 3 group) or group 2 (with omega 3 group). The intervention includes Zocular in clinic at baseline, Thealoz Duo eyedrops twice daily until surgery, and the cleansing wipes twice daily until surgery. The omega 3 group will take the supplement from baseline until one month post-operative.
Data will be collected for inflammation through a InflammaDry Matrix metallopeptidase 9 (MMP-9) test, dry eye through Oculus 5M (measures non-invasive break-up time (NIBUT), lipid layer, bulbar redness, tear meniscus height) and Canadian Dry Eye Assessment (CDEA), TearLab for osmolarity, and conjunctival swabs for microbial load. Dry eye metrics (CDEA and Oculus 5M) will be collected during the patient's baseline Cataract Dry Eye Clinic (CDEC) appointment, 2-5 days prior to surgery, and post-operative month 1. Microbial load will be collected at baseline, 2-5 days prior to surgery, and date of the surgery. Tear osmolarity and inflammation markers will be collected at baseline, 2-5 days prior to surgery, and post-operative month. An ocular assessment will also be completed at baseline, one week post-operation, and post-operative month. All metrics will be compared to the fellow eye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will take oral omega-3 supplement for 4 weeks pre-operatively and 4 weeks post-operatively. They will also receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.
Dietary Supplement: Omega-3 · Drug: Trehalose · Drug: Zocular Eyelid System Treatment · Other: Blephadex cleansing eyelid wipes
Participants in this arm will not take oral omega-3 supplement. They will only receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.
Drug: Trehalose · Drug: Zocular Eyelid System Treatment · Other: Blephadex cleansing eyelid wipes
Omega-3 is a fatty acid and there is evidence that the consumption of re-esterified oral omega-3 supplements over the course of 6 to 8 weeks aid in reducing inflammation, dry eye, and optimizing tear osmolarity. The oral omega-3 supplement taken daily.
Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.
Also known as: Thealoz Duo Drops
A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.
Also known as: ZEST
Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.
MMP-9
Level of MMP-9, an inflammatory marker reported as positive (level of MMP-9 \> 40ng/mL) or negative (level of MMP-9 \< 40ng/mL).
Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1
Microbial load
Area of microbial growth from conjunctival swab reported as percentage of dish coverage, incubated for 48 hours
Time frame: Baseline, 2-5 days prior to surgery, surgery day
Tear osmolarity
Measure of salt concentration in tear reported as mOsm/L
Time frame: Baseline, 2-5 days prior to surgery, surgery day
Non-invasive break-up time (NIBUT)
Non-invasive break-up time (NIBUT) is measured using the Oculus 5M and measured in seconds, with longer NIBUT representing better outcomes.
Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1
Lipid layer
Lipid layer is reported in nanometres with higher/thicker lipid layers representing a better outcome.
Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1
Bulbar redness
Bulbar redness is reported by a score from 0-4 with lower scores representing a better outcome.
Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1
Tear meniscus height
Tear meniscus height (TMH) is reported in millimetres, with increases in TMH representing a better outcome.
Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1
Canadian Dry Eye Assessment (CDEA) Questionnaire
12 item questionnaire for reporting of dry eye symptoms on a scale of 0-4. Total scores for the CDEA questionnaire range from 0 to 48 and are interpreted as no dry eye symptoms or normal (\<5), mild dry eye symptoms (5-20), moderate dry eye symptoms (21-30), or severe dry eye symptoms (31-48).
Time frame: Baseline, 2-5 days prior to surgery, post-operative month 1
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2023; primary completion for Jan 2024, 4 months later.
Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 4 months is below that.
Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omega-3 fatty acid
Uptown Eye Specialists